Value of tumor mutation burden in predicting efficiency of immunotherapy for patients with colorectal cancer

ZHANG Aolun; YIN Ting; ZHANG Xizhi

doi:10.7619/jcmp.202008035

Journal of Clinical Medicine in Practice > 2020 > 24(8): 128-132. > DOI: 10.7619/jcmp.202008035

ZHANG Aolun, YIN Ting, ZHANG Xizhi. Value of tumor mutation burden in predicting efficiency of immunotherapy for patients with colorectal cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(8): 128-132. DOI: 10.7619/jcmp.202008035

Citation:

PDF (658 KB)

Value of tumor mutation burden in predicting efficiency of immunotherapy for patients with colorectal cancer

1. Medical College of Yangzhou University, Yangzhou, Jiangsu, 225009;
2. Department of Oncology, Subei People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225001

More Information

Received Date: February 06, 2020

Graphical Abstract

Abstract

Abstract

At present, the treatment of colorectal cancer has changed from the inherent treatment mode of "surgery as the main therapy, radiotherapy and chemotherapy as adjuvant therapy" to the precise and individualized treatment concept, and immunotherapy has been paid more and more attention. However, not all the patients respond to immunocheckpoint inhibitors. Therefore, predicting the possibility of treatment response will help to screen the patients who can benefit. Many studies have shown that tumor mutation load has a positive correlation with the efficacy of immunosuppressive checkpoint inhibitors, and it can become an independent biomarker of immunotherapy. In this study, the prediction value and application status of tumor mutation load in immunotherapy of patients with colorectal cancer were reviewed.
- immunotherapy,
- immune checkpoint,
- colorectal cancer,
- tumor mutation burden,
- programmed death protein,
- microsatellite stability

FullText(HTML)

References (35)

References

Cai Z J, Liu Q. Understanding the Global Cancer Statistics 2018: implications for cancer control[J]. Sci China Life Sci, 2019: 1-4.

李鹏, 王拥军, 陈光勇, 等. 中国早期结直肠癌及癌前病变筛查与诊治共识[J]. 中国医刊, 2015, 50(2): 14-30.

Wang C H, Yu X T, Wang W. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer[J]. Medicine(Baltimore), 2016, 95(52): e5539-e5545.

Lin Z J, Chen X, Li Z F, et al. PD-1 antibody monotherapy for malignant melanoma: a systematic review and meta-analysis[J]. PLoS One, 2016, 11(8): e0160485.

Le D T, Durham J N, Smith K N, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.

Goodman A M, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers[J]. Mol Cancer Ther, 2017, 16(11): 2598-2608.

Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of response to anti-programmed cell death(PD)-1 and anti-programmed death-ligand 1(PD-L1)blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing[J]. J Clin Oncol, 2018, 36(7): 633-641.

Carbone D P, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer[J]. N Engl J Med, 2017, 376(25): 2415-2426.

McGranahan N, Furness A J, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade[J]. Science, 2016, 351(6280): 1463-1469.

Yi M, Qin S, Zhao W H, et al. The role of neoantigen in immune checkpoint blockade therapy[J]. Exp Hematol Oncol, 2018, 7: 28-32.

Ott P A, Hu Z T, Keskin D B, et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature, 2017, 547(7662): 217-221.

Keskin D B, Anandappa A J, Sun J, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial[J]. Nature, 2019, 565(7738): 234-239.

Zaravinos A, Roufas C, Nagara M, et al. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer[J]. J Exp Clin Cancer Res, 2019, 38(1): 364.

Panda A, Betigeri A, Subramanian K, et al. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors[J]. JCO Precis Oncol, 2017, 2017: 146-154.

Endris V, Buchhalter I, Allgäuer M, et al. Measurement of tumor mutational burden(TMB)in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels[J]. Int J Cancer, 2019, 144(9): 2303-2312.

Schrock A B, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer[J]. Ann Oncol, 2019, 30(7): 1096-1103.

Dung T L, Jennifer N U, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 373(20): 1979-1986.

Le D T, Uram J N, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26): 2509-2520.

Ritterhouse L L. Tumor mutational burden[J]. Cancer Cytopathol, 2019, 127(12): 735-736.

Fabrizio D A, George T J Jr, Dunne R F, et al. Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition[J]. J Gastrointest Oncol, 2018, 9(4): 610-617.

Giannakis M, Mu X J, Shukla S A, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma[J]. Cell Rep, 2016, 17(4): 1206-1213.

Briggs S, Tomlinson I. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers[J]. J Pathol, 2013, 230(2): 148-153.

Stadler Z K, Battaglin F, Middha S, et al. Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels[J]. J Clin Oncol, 2016, 34(18): 2141-2147.

Mlecnik B, Bindea G, Angell H K, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability[J]. Immunity, 2016, 44(3): 698-711.

Gong J, Robertson M D, Kim E, et al. Efficacy of PD-1 blockade in refractory microsatellite-stable colorectal cancer with high tumor mutation burden[J]. Clin Colorectal Cancer, 2019, 18(4): 307-309.

Pai S G, Carneiro B A, Chae Y K, et al. Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer[J]. J Gastrointest Oncol, 2017, 8(5): 858-866.

Klempner S J, Fabrizio D, Bane S, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence[J]. Oncologist, 2020, 25(1): e147-e159.

Chalmers Z R, Connelly C F, Fabrizio D, et al. Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden[J]. Genome Med, 2017, 9(1): 34-39.

Chowell D, Morris L G T, Grigg C M, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy[J]. Science, 2018, 359(6375): 582-587.

Turajlic S, Litchfield K, Xu H, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a Pan-cancer analysis[J]. Lancet Oncol, 2017, 18(8): 1009-1021.

Fabrizio D, Malboeuf C, Lieber D, et al. Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood(bTMB)to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial(BFAST)[J]. Ann Oncol, 2017, 28(Suppl 5): 27-35.

Büttner R, Longshore J W, López-Ríos F, et al. Implementing TMB measurement in clinical practice: considerations on assay requirements[J]. ESMO Open, 2019, 4(1): e000442.

Samstein R M, Lee C H, Shoushtari A N, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Genet, 2019, 51(2): 202-206.

Wolchok J D, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356.

Hellmann M D, Callahan M K, Awad M M, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer[J]. Cancer Cell, 2019, 35(2): 329-335.

Cited By

Get Citation

PDF

XML

Article views (428) PDF downloads (18)

Turn off MathJax

Article Contents

Abstract

References

Value of tumor mutation burden in predicting efficiency of immunotherapy for patients with colorectal cancer

Abstract

References

Catalog

Export File

Citation

Format

Content